Document:

Exhibit

Exhibit 4.6

AMENDMENT NO. 1 TO CREDIT AGREEMENT 
AND PARENT JOINDER AGREEMENT

AMENDMENT NO. 1 TO THE CREDIT AGREEMENT AND PARENT JOINDER AGREEMENT (this “Amendment”), dated as of September 28, 2015, among BLUE BIRD CORPORATION (f/k/a Hennessy Capital Acquisition Corp.), a Delaware corporation (the “Parent”), SCHOOL BUS HOLDINGS INC., a Delaware corporation (“School Bus Holdings”), PEACH COUNTY HOLDINGS INC., a Delaware corporation, and BLUE BIRD GLOBAL CORPORATION (f/k/a Blue Bird Corporation), a Delaware corporation (collectively, the “Intermediate Parents”), BLUE BIRD BODY COMPANY, a Georgia corporation (the “Borrower”), each other Loan Party party hereto, each Lender party hereto and Société Générale (acting through one or more of its branches or any Affiliate thereof, collectively, “SG”), as Administrative Agent (in such capacity, the “Administrative Agent”).  Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement referred to below.
PRELIMINARY STATEMENTS:
WHEREAS, School Bus Holdings, the Intermediate Parents, the Borrower, the Lenders party thereto and Société Générale, as Administrative Agent, entered into that certain Credit Agreement, dated as of June 27, 2014 (as it may be amended, restated, supplemented, or otherwise modified from time to time, the “Credit Agreement”);
WHEREAS, the Parent consummated a Qualified IPO on February 24, 2015;
 WHEREAS, the Parent will join the Credit Agreement and the other Loan Documents as a Guarantor thereunder and, from and after the Amendment No. 1 Effective Date (as defined in Section 2 below), shall assume all the obligations of Holdings and a Loan Party for all purposes under the Credit Agreement and the other Loan Documents; and
WHEREAS, the Borrower wishes to effect an extension of the maturity date of the Revolving Facility and certain additional amendments to the Credit Agreement as set forth herein;
NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the Borrower, the other Loan Parties party hereto, the Parent, the Administrative Agent and the Lenders party hereto have agreed to amend the Credit Agreement on the terms and conditions hereinafter set forth.
SECTION 1.Amendments to the Credit Agreement.  The Credit Agreement is, effective as of the Amendment No. 1 Effective Date, hereby amended as follows:
(a)Section 1.01 of the Credit Agreement is amended by adding in the appropriate alphabetical order the following new definitions:
“Amendment No. 1” means Amendment No. 1 to this Agreement, dated as of September 28, 2015, among the Parent, School Bus Holdings, the Intermediate Parents, the Borrower, the other Loan Parties party thereto, the Administrative Agent and the Lenders party thereto.
“Amendment No. 1 Effective Date” means the date on which all the conditions precedent to effectiveness of Amendment No. 1, as set forth therein, are satisfied or waived in accordance therewith.
“Blue Bird Global” means Blue Bird Global Corporation (f/k/a Blue Bird Corporation), a Delaware corporation.
“Capitalized Dividend Payments” means, with respect to the Preferred Shares, the payment of any portion of dividends on such shares with the issuance of additional Preferred Shares or common Equity Interests of Holdings, and not in cash, pursuant to the terms of the Preferred Shares Certificate of Designations.

Exhibit 4.6

“Dividend Payment Date” means, with respect to any issued and outstanding Preferred Shares, March 15, June 15, September 15 and December 15 of each applicable fiscal year, beginning with December 15, 2015.
“Internally Generated Cash Flow” means, with respect to any period, any cash of the Borrower and its Restricted Subsidiaries generated during such period, excluding the Net Proceeds of and any cash that is generated from incurrence of Indebtedness or issuance of (or contributions in respect of) any Equity Interests.
“Parent” means Blue Bird Corporation (f/k/a Hennessy Capital Acquisition Corp.), a Delaware corporation, of which School Bus Holdings is a direct, wholly-owned Subsidiary.
“Peach County Holdings” means Peach County Holdings Inc., a Delaware corporation.
“Preferred Shares” means the 7.625% Series A Convertible Cumulative Preferred Stock of Holdings issued in accordance with that certain Second Amended and Restated Certificate of Incorporation of Holdings, dated as of February 24, 2015, and the Preferred Shares Certificate of Designation of which 729,435 total preferred shares have been issued and remain outstanding as of the Amendment No. 1 Effective Date, as such amount may be decreased or increased, as the case may be, from time to time upon cancellation of any thereof or conversion of any portion of such Preferred Shares to common stock of Holdings or upon payment of any Capitalized Dividend Payments, in each case, in accordance with the terms of the Preferred Shares Certificate of Designations as in effect on February 24, 2015.
“Preferred Shares Certificate of Designations” means that certain Certificate of Designations, Preferences, Rights and Limitations of 7.625% Series A Convertible Cumulative Preferred Stock of Holdings, as in effect on February 24, 2015, and as filed with the Secretary of State of the State of Delaware on such date.  
“School Bus Holdings” means School Bus Holdings Inc., a Delaware corporation.
“Specified Preferred Share Dividend Payment” means, as of any Dividend Payment Date, the payment of cash dividends in respect of the aggregate issued and outstanding Preferred Shares as of the relevant dividend record date set forth in the Preferred Shares Certificate of Designations, as and when declared by the board of directors of Holdings and in such dollar amounts as are determined, in each case, in accordance with the terms of the Preferred Shares Certificate of Designations.
“Warrants” means the warrants issued to purchase one-half of a share of the common stock of Parent at a price of $5.75 per half share, issued by Parent, of which 11,500,000 Warrants are outstanding as of the Amendment No. 1 Effective Date.
(b)Section 1.01 of the Credit Agreement is further amended by amending the definition of:
(i)“Available Amount” by (x) adding “plus” at the end of clause (b)(iii) thereto and adding a new clause (b)(iv) to read as follows:
“(iv)  the aggregate amount of Restricted Payments made in reliance on Section 6.06(a)(xi) prior to the Reference Time.” 
(ii)“Consolidated EBITDA” by deleting “and” at the end of clause (i)(M) thereto and adding a new clause (i)(O) thereto to read as follows:
“(O)    third-party costs and expenses incurred in connection with compliance with and filings relating to public company requirements and regulations, including, costs relating to audit fees and quarterly reviews, legal expenses, Directors & Officers liability insurance costs and related expenses and director’s fees and expenses.”

Exhibit 4.6

(iii)“Excess Cash Flow” by amending:
(1)clause (b)(v) therein by replacing the reference to “internally generated cash flow” contained in the third line therein with “Internally Generated Cash Flow” in place thereof; and
(2)clause (b)(vi) by amending and restating it in its entirety to read as follows:
“the amount of dividends paid and other Restricted Payments made during such period pursuant to Sections 6.06(a)(iv), 6.06(a)(v)(B), 6.06(a)(v)(C), 6.06(a)(v)(E), 6.06(a)(ix) and 6.06(a)(x), in each case, to the extent such dividends or other Restricted Payments were financed with Internally Generated Cash Flow,”
(iv)“Holdings” is amended and restated in its entirety to read as follows:
“‘Holdings’ means, (a) prior to the effectiveness of Amendment No. 1, School Bus Holdings and (b) from and after the effectiveness of Amendment No. 1, the Parent.”.
(v)“Indebtedness” is amended by adding at the end thereof a new sentence to read:  “For the avoidance of doubt, obligations in respect of the Preferred Shares shall not constitute Indebtedness.”.
(vi)“Intermediate Parent” is amended and restated in its entirety to read as follows:
“‘Intermediate Parent’ means, (a) prior to the Amendment No. 1 Effective Date, (i) Peach County Holdings and (ii) Blue Bird Global; and (b) from and after the Amendment No. 1 Effective Date, (i) School Bus Holdings, (ii) Peach County Holdings, (iii) Blue Bird Global and (iv) any other Wholly Owned Subsidiary of Holdings and of which the Borrower is a Wholly Owned Subsidiary.”. 
(vii)“Revolving Maturity Date” is amended by replacing the reference to “fifth anniversary” contained therein with “sixth anniversary” in place thereof.
(c)Section 6.03(a) of the Credit Agreement is amended by: 
(i) amending and restating clause (i) thereto in its entirety to read as follows:
“(i)    (A) Holdings or any Intermediate Parent may merge, amalgamate, consolidate with and into Holdings or any Intermediate Parent; provided that Holdings shall be the continuing or surviving Person, (B) any Restricted Subsidiary or Intermediate Parent may merge with and into the Borrower; provided that the Borrower is the continuing or surviving Person, or (C) in the case of any Restricted Subsidiary (other than the Borrower), any one or more other Restricted Subsidiaries; provided that when any Subsidiary Loan Party is merging with another Subsidiary (1) the continuing or surviving Person shall be a Subsidiary Loan Party or (2) if the continuing or surviving Person is not a Subsidiary Loan Party,  the acquisition of such Subsidiary Loan Party by such surviving Restricted Subsidiary is otherwise permitted under Section 6.04;”; and
(ii) deleting “and” at the end of clause (v) thereto, (ii) replacing the “.” at the end of clause (vi) with “;” and (iii) a new clause (vii) to read as follows:
“(vii)    The Borrower may, upon not less than thirty (30) days’ prior notice to the Administrative Agent (or such shorter period as the Administrative Agent may reasonably agree), elect to convert its corporate form to a limited liability company organized in the State of Delaware or in any other United States jurisdiction reasonably satisfactory to the Administrative Agent; provided that (i) its constitutive documents will expressly provide that the Equity Interests in the Borrower are a “security” governed by Article 8 of the Uniform Commercial Code, (ii) its Equity Interests shall be certificated and pledged to the Administrative Agent, together with appropriate transfer powers endorsed in blank, and (iii) the Borrower shall have delivered, recorded or effected such other filings, notices and recordations as the Administrative Agent may deem reasonably necessary or desirable for the Collateral and Guarantee Requirements to be satisfied.”.

Exhibit 4.6

(d)Section 6.03(c) of the Credit Agreement is amended by adding a new parenthetical immediately following the reference to “issuance or registration of its Equity Interests” contained in clause (iv) therein to read “(including, for the avoidance of doubt, the Preferred Shares)”.
(e)Section 6.06(a) of the Credit Agreement is amended by:
(i)amending clause (ii) thereof by adding “or, in the case of the Preferred Shares, in additional Preferred Shares in accordance with the terms of the Preferred Shares Certificate of Designations” at the end thereof.
(ii)amending clause (vi) therein by replacing the figure “1.75” contained therein with the figure “2.75” in place thereof; 
(iii) (x) deleting “and” at the end of clause (a)(vii) therein, (y) replacing the “.” at the end of clause (a)(viii) therein with a “,” and (z) adding a new clause (a)(ix) thereafter to read as follows:
“(ix)    from and after the Amendment No. 1 Effective Date, the Borrower and any Intermediate Parent may make Restricted Payments to Holdings, which proceeds shall be applied by Holdings or any Intermediate Parent to make Restricted Payments in an amount not to exceed the cash portion, if any, of Specified Preferred Share Dividend Payments that (A) have accrued and are due and payable as of the applicable Dividend Payment Date and (B) have been declared by the board of directors of Holdings as cash dividends for such Dividend Payment Date in respect of Preferred Shares then outstanding, in each case, in accordance with the terms of the Preferred Shares Certificate of Designations; provided, that (1) the proceeds of such Restricted Payments permitted under this Section 6.06(a)(ix) shall be used solely to pay Specified Preferred Share Dividend Payments that are due and owing, (2) such Restricted Payments shall be made not more than quarterly and (3) no Event of Default has occurred or would result, after giving Pro Forma Effect to such Restricted Payment, at the time such Specified Preferred Share Dividend Payments is declared.”; and 
(iv)adding a new clause (x) thereto to read as follows:
“(x)    from and after the Amendment No. 1 Effective Date, Holdings, the Borrower and any Intermediate Parent may make additional Restricted Payments; provided that (1) no Event of Default exists or would result therefrom and (2) the Total Net Leverage Ratio, on a Pro Forma Basis as of the end of the most recently ended Test Period after giving effect to such Restricted Payment, does not exceed 2.25 to 1.00; and”; and    
(v)adding a new clause (xi) thereto to read as follows:
(xi)  from and after the Amendment No. 1 Effective Date, Holdings, the Borrower and any Intermediate Parent may make Restricted Payments in an aggregate total amount not to exceed the Available Amount at such time, which proceeds shall be applied to finance the tender offer by Holdings of outstanding Warrants in accordance with the terms thereof; provided, that (1) the proceeds of such Restricted Payments permitted under this Section 6.06(a)(xi) shall be used solely to finance the specified tender offer of Warrants and (2) no Event of Default has occurred or would result from such Restricted Payment on a Pro Forma Basis.”.
(f)Section 6.06(b)(iv) of the Credit Agreement is amended by replacing the figure “2.25” contained therein with “2.75” in place thereof.
(g)Section 6.07 of the Credit Agreement is amended by replacing the reference to “the Effective Date” contained in clause (vi) thereto with “the Amendment No. 1 Effective Date” in place thereof.
(h)Schedule 3.12 of the Credit Agreement is hereby supplemented with the supplement thereto annexed hereto as Schedule 3.12.
(i)Schedule 6.07 is hereby supplemented with the supplement thereto annexed hereto as Schedule 6.07.
(j)The Credit Agreement and each other Loan Document is further amended by replacing all references to “Blue Bird Body Corporation” contained in each therein with “Blue Bird Global Corporation” in place of each thereof.

Exhibit 4.6

SECTION 2.Conditions to Effectiveness.  This Amendment shall become effective as of the date (the “Amendment No. 1 Effective Date”) when, and only when, each of the following conditions have been satisfied or waived in accordance with the terms therein:
(a)The Administrative Agent shall have received counterparts of this Amendment executed by (i) the Administrative Agent, (ii) the Borrower and each other Loan Party and Blue Bird Corporation, and (iii) the Required Lenders and (iv) solely with respect to the amendment specified in Section 1(b)(vii) herein, Lenders representing 100% of Revolving Commitments;
(b)The Borrower shall have paid, (i) for the account, without duplication, of each Lender that has returned an executed signature page to this Amendment (each such Lender, a “Consenting Lender”) at or prior to 5:00 pm (New York City time) on Thursday, September 24, 2015, fees in the amount equal to 0.125% of the sum of such Consenting Lender’s (x) principal amount of outstanding Term Loans, in the case of a Term Lender, and (y) Revolving Commitments in the case of a Revolving a Lender, in each case, as in effect immediately prior to the Amendment No. 1 Effective Date; (ii) all fees payable to SG and the Administrative Agent as agreed in writing with the Borrower; and (iii) all reasonable and documented out-of-pocket fees and expenses (limited to, with respect to legal fees and costs, the reasonable and documented out-of-pocket fees and expenses of Paul Hastings LLP) incurred by the Administrative Agent in connection with the preparation, negotiation and execution of this Amendment and other matters relating to the Loan Documents.  
(c)the Administrative Agent shall have received a (i) certificate of a Responsible Officer of each Loan Party and the Parent, dated the Amendment No. 1 Effective Date, certifying that attached thereto is a true and complete copy of resolutions duly adopted by the board of directors (or other equivalent governing body) of such Loan Party and the Parent authorizing the execution, delivery and performance of the Loan Documents to which such person is a party and that such resolutions have not been modified, rescinded or amended and are in full force and effect; (ii) such certificates of resolutions or other action, incumbency certificates evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as an Responsible Officer in connection with this Amendment and the other Loan Documents to which such Loan Party and the Parent is a party or is to be a party; and (iii) a good standing certificate (to the extent such concept exists) from the applicable Governmental Authority of each Loan Party’s and Parent’s jurisdiction of incorporation, organization or formation;
(d)(i) The representations and warranties of the Parent, the Borrower and each other Loan Party contained in this Amendment or any other Loan Document shall be true and correct in all material respects prior to and after giving effect to this Amendment and the transactions contemplated herein; provided that, to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided, further that, any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates; and provided, further, that the representation set forth in Sections 3.12 and 3.18 of the Credit Agreement as of the Amendment No. 1 Effective Date shall incorporate any relevant supplemental schedules included in any Joinder Agreements delivered pursuant to Section 2(g) hereto regarding necessary filings and actions to be undertaken to perfect the first priority security interest of the Administrative Agent in Collateral pledged by the Parent and any other Loan Party, (ii) no Default or Event of Default shall exist, or would result from (x) the consummation of the other transactions contemplated hereby, including from the application of the proceeds therefrom and (y) the amendments to the Loan Documents contemplated hereby, and the other transactions contemplated hereby; 
(e)the Administrative Agent shall have received a certificate dated as of the Amendment No. 1 Effective Date and executed by a Responsible Officer of the Borrower as to the matters set forth in Section 2(d) of this Amendment;
(f)the Administrative Agent shall have received, on behalf of itself and the Lenders, a favorable written opinion of (i) Schulte Roth & Zabel LLP, special counsel to the Loan Parties and (ii) Smith, Gambrell & Russell, LLP, Georgia counsel to the Loan Parties, in each case in form and substance reasonably satisfactory to the Administrative Agent;
(g)the Administrative Agent shall have received (x) Joinder Agreements with respect to the Collateral Agreement and Master Guarantee Agreement executed by the Parent, together with updated schedules to each thereof and updated schedules to the Credit Agreement, as applicable, and the information required to be provided pursuant to Section 5.03(a) of the Credit Agreement and (y) delivery of all certificates 

Exhibit 4.6

representing equity interests in School Bus Holdings, together with undated stock transfer powers endorsed in blank; and
(h)the Administrative Agent shall have received evidence that, substantially simultaneously with the effectiveness of this Amendment (or as otherwise agreed with the Administrative Agent), all actions, recordings and filings under the Uniform Commercial Code or otherwise required to be made pursuant to the Collateral and Guarantee Requirements with respect to the Parent and the other Loan Parties as requested by the Administrative Agent shall have been taken, completed or otherwise provided in a manner reasonably satisfactory to the Administrative Agent in order to create and maintain the Administrative Agent’s perfected first priority security interests in the Collateral, in the manner, and to the extent required by, the Collateral and Guarantee Requirements specified in the Credit Agreement, which requirements shall include the requirements of Section 5.12 of the Credit Agreement and shall include the delivery of a recent Lien and judgment search with respect to the Parent in each jurisdiction reasonably requested by the Administrative Agent.
For purposes of determining compliance with the conditions specified in this Section 3, each Lender shall be deemed to have consented to, approved or accepted or to be satisfied with each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to the Lenders unless an officer of the Administrative Agent responsible for the transactions contemplated by the Loan Documents shall have received written notice from such Lender prior to the Amendment No. 1 Effective Date specifying its objection thereto.
SECTION 3.Parent Joinder to Credit Agreement.  By execution of this Amendment, the Parent hereby acknowledges, agrees and confirms that, from and after the Amendment No. 1 Effective Date, the Parent will be deemed to be a Loan Party under the Credit Agreement and a Guarantor for all purposes of Credit Agreement and each other Loan Document and shall have all of the rights, benefits, duties and obligations of a Loan Party and a Guarantor.  By execution of this Agreement, the Parent hereby assumes any all the duties and obligations of “Holdings” and of a Guarantor thereunder as if it had executed the Credit Agreement and all applicable Loan Documents.  The Parent hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Credit Agreement, including, without limitation, (a) all of the representations and warranties of the Loan Parties set forth in Article III of the Credit Agreement and (b) all of the covenants set forth in Articles V and VI of the Credit Agreement.  The Parent hereby agrees that each reference to a (a) “Holdings” in the Credit Agreement or any other Loan Document shall include the Parent, except as provided therein, (b) “Guarantor” or “Guarantors” in the Credit Agreement or any other Loan Document shall include the Parent, except as provided therein and (e) “Grantor” or “Grantors” in the Collateral Agreement or any other Loan Document shall include the Parent, except as provided therein.  The Parent acknowledges that it has received a copy of the Credit Agreement and the other Loan Documents and that it has read and understands the terms of each thereof.  The Parent hereby acknowledges and agrees that this Agreement is a Loan Document and each reference in the Credit Agreement or any Loan Document to the “Loan Documents” shall mean and include a reference to this Amendment and Joinder Agreement.  
SECTION 4. Consent and Affirmation of the Loan Parties.  Each Loan hereby consents to the amendment of the Credit Agreement and the other Loan Documents effected hereby and confirms and agrees that, notwithstanding the effectiveness of this Amendment, each Loan Document to which such Loan Party is a party is, and the obligations of such Loan Party contained in the Credit Agreement, this Amendment or in any other Loan Document to which it is a party, are and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects, in each case as amended by this Amendment.  For greater certainty and without limiting the foregoing, each Loan Party hereby confirms that the existing security interests granted by such Loan Party in favor of the Secured Parties pursuant to the Loan Documents in the Collateral described therein shall continue to secure the obligations of the Loan Parties under the Credit Agreement and the other Loan Documents as and to the extent provided in the Loan Documents.
SECTION 5.Confirmation of Representations and Warranties.  (a) Each Loan Party and the Parent hereby represents and warrants, on and as of the Amendment No. 1 Effective Date, that the representations and warranties contained in the Loan Documents are true and correct in all material respects on and as of the Amendment No. 1 Effective Date, before and after giving effect to this Amendment, as though made on and as of the Amendment No. 1 Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall have been true and correct in all material respects as of such earlier date, and except that any 

Exhibit 4.6

representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language is true and correct (after giving effect to any qualification therein) in all respects as of such respective dates.
(a)Each Loan Party and the Parent represents and warrants, on and as of the Amendment No. 1 Effective Date, that: (i) it has the requisite power to execute and deliver this Amendment, and all corporate or other action required to be taken by it for the due and proper authorization, execution, delivery and performance of this Amendment and the consummation of the transactions contemplated hereby has been duly and validly taken; (ii) this Amendment has been duly authorized, executed and delivered by it; and (iii) no order, consent, approval, license, authorization or validation of or filing, recording or registration or exemption by or any other action by any Governmental Authority is or will be required in connection with the execution and delivery of this Amendment.
(b)Each Loan Party and the Parent hereby represents and warrants that both immediately before and after giving effect to the Amendment, no event has occurred and is continuing that constitutes a Default or Event of Default or would result therefrom.
SECTION 6.Reference to and Effect on the Credit Agreement and the other Loan Documents.
(a)On and after the effectiveness of this Amendment, each reference in the Credit Agreement and the other Loan Documents to “this Amendment”, “hereunder”, “hereof’ or words of like import referring to the Credit Agreement or such other Loan Document shall mean and be a reference to the Credit Agreement or such Loan Document as amended by this Amendment.
(b)The Credit Agreement and each other Loan Document as specifically amended by this Amendment are and shall continue to be in full force and effect and are hereby in all respects ratified, consented to and confirmed.  This Amendment shall be a “Loan Document” for purposes of the definition thereof in the Credit Agreement and the other Loan Documents.
(c)The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under the Credit Agreement or any other Loan Document.
SECTION 7.Expenses.  Each of the Loan Parties hereby reconfirms its respective obligations pursuant to Section 9.03 (and subject to any limitations set forth therein) of the Credit Agreement to pay the reasonable and documented or invoiced out-of-pocket expenses incurred by the Administrative Agent in connection with this Amendment.
SECTION 8.Loan Document.  The parties hereto acknowledge and agree that this Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents.
SECTION 9.Execution in Counterparts.  This Amendment may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute one and the same instrument.  Delivery of an executed counterpart of a signature page of this Amendment by email, telecopy or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Amendment.
SECTION 10.Governing Law.  This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York.
SECTION 11.Headings.  Section headings are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.
SECTION 12.Severability.  In case any provision in or obligation hereunder shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired hereby.
SECTION 13.Notices; Successors; Waiver of Jury Trial.  All communications and notices hereunder shall be given as provided in the Credit Agreement.  The terms of this Amendment shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.  Each of the parties hereto irrevocably waives trial by jury in any action or proceeding with respect to this Amendment or any other Loan Document.
 [Signature Pages Follow.][Blue Bird - Amendment No. 1 - Signature Page]
LEGAL_US_E # 116810117.10 

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their respective Responsible Officers as of the date first above written.

Exhibit 4.6

BLUE BIRD BODY COMPANY, 
as the Borrower

                                                              	
	
	By: /s/ Philip Horlock

	Philip Horlock

	President and Chief Executive Officer

	(principal executive officer)

BLUE BIRD CORPORATION (f/k/a Hennessy Capital Acquisition Corp.), as Holdings and as Guarantor

                                                                      	
	
	By: /s/ Philip Horlock

	Philip Horlock

	President and Chief Executive Officer

	(principal executive officer)

SCHOOL BUS HOLDINGS INC., 
as Intermediate Parent and as Guarantor

                                                                        	
	
	By: /s/ Philip Horlock

	Philip Horlock

	President and Chief Executive Officer

	(principal executive officer)

PEACH COUNTY HOLDINGS INC., 
as Intermediate Parent and as Guarantor

                                                                	
	
	By: /s/ Philip Horlock

	Philip Horlock

	President and Chief Executive Officer

	(principal executive officer)

BLUE BIRD GLOBAL CORPORATION (f/k/a Blue Bird Corporation), as an Intermediate Parent and as Guarantor
                                                             	
	
	By: /s/ Philip Horlock

	Philip Horlock

	President and Chief Executive Officer

	(principal executive officer)

Exhibit 4.6

Société Générale, 
as Administrative Agent
                                                                    	
	
	By: /s/ Carol Radice

	Carol Radice

	Director

 

Société Générale, 
as Required Lender and Revolving Lender
	
	
	By: /s/ Michael Finkelman

	Michael Finkelman

	Managing Director

LEGAL_US_E # 116810117.10 

 Schedule 3.12
to Amendment No. 1 and Joinder Agreement

Supplement to Schedule 3.12 of the Credit Agreement
Subsidiaries
	
			
	Loan Party
	Name of Subsidiary
	Percentage of Subsidiary Owned by such Loan Party

	Blue Bird Corporation (f/k/a Hennessy Acquisition Capital Corp.)
	Schools Bus Holdings Inc.
	100%

Schedule 6.07
to Amendment No. 1 and Joinder Agreement

Supplement to Schedule 6.07 of the Credit Agreement
Existing Affiliate Transactions
		
	1.
	Registration Rights Agreement, dated February 24, 2014, by and among Blue Bird Corporation (formerly known as Hennessy Capital Acquisition Corp.), The Traxis Group B.V., The Osterweis Strategic Income Fund, The Osterweis Strategic Investment Fund, Overland Relative Value Master Fund LP, Overland Viceroy Master Fund, Coliseum School Bus Holdings, LLC, Coliseum Capital Partners, L.P., Coliseum Capital Partners II, L.P. and Blackwell Partners LLC - Series A, entered pursuant to the terms of a purchase agreement, dated as of September 21, 2014 (as amended on February 10, 2015 and February 18, 2015), in connection with the purchase by the Parent of all of the outstanding capital stock of School Bus Holdings Inc., as such Registration Rights Agreement is in effect on the Amendment No. 1 Effective Date.

		
	2.
	Lock-Up Letter Agreement, dated February 24, 2015, by The Traxis Group B.V., entered pursuant to the terms of a purchase agreement, dated as of September 21, 2014 (as amended on February 10, 2015 and February 18, 

Exhibit 4.6

2015), in connection with the purchase by the Parent of all of the outstanding capital stock of School Bus Holdings Inc., as such Lock-Up Letter Agreement is in effect on the Amendment No. 1 Effective Date.Exhibit 10.1

 

 

December
14, 2015

 

 

Kenneth S. Kornman

920 Centre Street

Newton, MA 02459

 

Re:Agreement of Employment

 

Dear Ken:

 

I am pleased to provide
you with this agreement (the “Letter Agreement”), which provides the terms and conditions of your continued employment
by Interleukin Genetics, Inc. (“Interleukin”).

 

1.Commencement
Date. This Letter Agreement shall be effective as of December 1, 2015. This agreement is intended to replace that certain
Employment Agreement, dated November 12, 2008, as amended on March 31, 2012 and November 29, 2012, by and between you and Interleukin,
which terminated by its terms as of November 30, 2015 (the “Prior Agreement”).

 

2.Position
and Responsibilities. Your position will be President and Chief Scientific Officer. As an Interleukin employee, we expect
you to devote all of your professional and working time and energies to the business and affairs of Interleukin, and to perform
any and all duties and responsibilities that are associated with this position and such additional duties and responsibilities
that the management of Interleukin otherwise may assign to you; provided, however, that the foregoing requirements will not prohibit
you from devoting reasonable time to (i)  serving as a director, committee member or scientific editor of any organization
that does not compete with Interleukin or that does not involve a conflict of interest with Interleukin; (ii) managing your personal
investments; so long as in either case, such activities do not materially interfere with the regular performance of your duties
under this Agreement; or (iii) delivering scientific lectures in the area of Periodontal Disease and Treatment and such other scientific
areas, as shall be approved by the CEO or the Board. You agree to abide by all reasonable employment policies instituted by Interleukin,
as they may be instituted or amended from time to time. Your performance will be reviewed on a periodic basis, but no less frequently
than annually, as long as you remain employed by Interleukin.

 

3.At-Will
Nature of Relationship. No provision of this Letter Agreement will be construed to create an express or implied employment
contract, or a promise of employment for any specific period of time. Your employment with Interleukin is at-will employment which
may be terminated by you or Interleukin at any time for any reason (or for no reason) with or without advance notice, subject
to your eligibility for specified types of severance payments upon specified types of terminations, as described in Section 5.

 

    	 	1	 

     

    

 

 

4.Compensation
and Benefits.

 

(a)Base Pay.
Your initial base pay will be $360,000 on an annualized basis (your “Base Pay”), less applicable taxes and standard
withholdings and deductions, paid in accordance with Interleukin’s standard payroll procedures. Interleukin will review your
Base Pay on an annual basis.

 

(b) Annual Bonus.
You are eligible to participate in the Interleukin Bonus Plan, with a target maximum annual bonus of thirty-five percent (35%)
of your Base Pay for the 2016 Bonus Plan Year. The annual bonus period will begin January 1, 2016 and will be pro-rated for any
period of inactive employment. The actual amount of any annual bonus will be determined by the Compensation Committee of the Interleukin
Board of Directors after assessing Interleukin goals and individual milestones. The annual bonus is expressly subject to your employment
through the date the annual bonus is paid, and will not be earned unless you are employed on such date. The Board’s Compensation
Committee has absolute discretion as to whether annual bonuses will be awarded and the size of any annual bonus, notwithstanding
whether any certain corporate goals are met.

 

(c)Equity.
Pursuant to and subject to the terms and conditions of the Interleukin Genetics Inc. 2013 Employee, Director and Consultant Equity
Incentive Plan (the “Plan”) and any applicable option agreement, Interleukin will grant you 400,000 options to purchase
shares of common stock of Interleukin at an exercise price equal to the Fair Market Value (as defined in the Plan) of the common
stock on the date of approval of the grant by the Board of Directors or an authorized committee thereof. The options will vest
over a four (4) year period in 48 equal monthly installments on the first day of each month beginning on January 1, 2016. Notwithstanding
the foregoing, if at any time within ninety (90) days prior to or twelve (12) months following the effective date of a Change in
Control (as defined below), you are terminated without Cause (as defined in Section 5(a) below), then this option shall become
fully vested and exercisable as of the date of such termination.

 

For purposes of
this section, “Change in Control” means the occurrence of any of the following events: (i) any “Person”
(as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “Beneficial Owner” (as defined in
Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), directly or indirectly, of
securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding
voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee
benefit plan of the Company) pursuant to a transaction or a series of related transactions; or (ii)(a) a merger or consolidation
of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities
of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted
into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented
by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding
immediately after such merger or consolidation; or (b) the sale or disposition by the Company of all or substantially all of the
Company’s assets in a transaction requiring stockholder approval.

 

(d)Vacation.
 You will be entitled to twenty (20) days of vacation per year, which will accrue ratably on an annual basis, subject to the
terms and conditions of Interleukin’s vacation policy.

 

    	 	2	 

     

    

 

 

(e)Fringe
Benefits. You may take advantage of various benefits offered by Interleukin, which currently include group medical and dental
insurance, short term disability coverage, group life insurance, and a 401(k) plan. Please note that Interleukin benefits may be
modified, changed or eliminated from time to time at the sole discretion of Interleukin, and the provision of such benefits to
you in no way changes or impacts your status as an at-will employee. Where a particular benefit is subject to a formal plan (for
example, medical insurance), eligibility to participate in and receive such benefit is governed solely by the applicable plan document.
Interleukin will pay life insurance premiums annually in the amount of $3,296.00 on a policy for you. You shall have the right
to designate ownership and beneficiary of said policy.

 

(f)Expense
Reimbursement. Interleukin will reimburse you for all ordinary and reasonable out-of-pocket business expenses incurred by you
in furtherance of Interleukin’s business in accordance with Interleukin’s policies with respect thereto as in effect
from time to time. All reimbursements provided under this Letter Agreement will be made or provided in accordance with the
requirements of Section 409A (“Section 409A”) of the Internal Revenue Code and the rules and regulations there under
(the “Code”) including, where applicable, the requirement that (A) any reimbursement is for expenses incurred
during your lifetime (or during a shorter period of time specified in this Agreement); (B) the amount of expenses eligible
for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year; (C)
the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which
the expense is incurred; and (D) the right to reimbursement or in kind benefits is not subject to liquidation or exchange
for another benefit.

 

5.Termination
Payments. As stated above, your employment with Interleukin is at-will employment, which may be terminated by you or Interleukin
at any time for any reason, with or without advance notice. Notwithstanding for the foregoing, the parties agree to the following
regarding payments on termination.

 

(a)Termination
without Cause. If your employment hereunder is terminated by Interleukin without Cause (as defined below) at any time, and
if you execute and do not revoke a release agreement in connection with such termination (as described in Section 5(c)), then:

 

(i)                
 Interleukin will pay you an amount equal to your Base Pay in effect at the time of such termination for a period commencing
on the effective date of the release agreement and ending on the six (6) month anniversary of such effective date.

 

For purposes of this
section, “Cause” means your: (i) willful misconduct or gross negligence that results in loss, damage or injury
to Interleukin; (ii) unauthorized disclosure of Interleukin trade secrets or confidential and proprietary information;
(iii) dishonesty of a material nature (including, but not limited to, theft or embezzlement of Interleukin funds or assets),
willful disloyalty, or breach of fiduciary duty to Interleukin or its shareholders; (iv) breach of your obligations under
this Letter Agreement or your Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement; (v)
failure to perform your responsibilities or duties as an employee of Interleukin, which failure has not been cured within thirty
(30) days after written notice thereof to you by Interleukin; or (vi) commission of, or plea of guilty or nolo contendere
to, a felony (excluding minor traffic violations).

 

    	 	3	 

     

    

 

 

(b)Other Termination.
If your employment hereunder is terminated by you at any time for any reason, or by Interleukin in any circumstances or for any
reason other than those specifically described in Section 5(a), then you will not be eligible for any form of severance pay, benefits
or compensation, other than Accrued Obligations described below.

 

(c)Release of
Claims; Timing of Payment. Interleukin will not be obligated to provide you with any payment or benefit described in Section
5(a) unless you execute and do not revoke a release agreement in a form acceptable to Interleukin, which will include (at a minimum)
a general release of claims against Interleukin and its affiliated entities and each of their officers, directors, employees and
others associated with Interleukin and its affiliated entities. The release agreement will be provided to you following your separation
of service from Interleukin, and must become effective and irrevocable before the sixtieth (60th) day following such
separation from service (the “Review Period”). If you sign and do not revoke the release agreement within the Review
Period, then applicable payments and benefits will be made or will commence, as applicable, on
Interleukin’s first regular payroll date following the conclusion of the Review Period, provided that if the Review Period
begins in one taxable year of yours and ends in a later taxable year of yours, then the payment(s) will commence in the later taxable
year. 

 

(d)Payment of
Accrued Obligations. You will be paid the following upon an employment termination, regardless of the reason therefor and/or
the application of any of the above sections: (i) the portion of your Base Pay that is accrued but not yet paid; (ii)
the portion of your vacation that is accrued and not yet used, pursuant to the terms of any applicable Interleukin policy; and
(iii) the business expenses properly incurred by you and not yet reimbursed, pursuant to the terms of any applicable Interleukin
policy. Your entitlement to any other compensation or benefit under any plan of Interleukin will be governed by and determined
in accordance with the terms of such plans.

 

6.Your Certifications.
By signing this Letter Agreement, you are certifying and representing to Interleukin that: (a) you are free to enter
into and fully perform the duties of your position; (b) you are not subject to any employment, confidentiality, non-competition
or other agreement that would restrict your right to work for Interleukin in any way, and you have provided Interleukin with a
copy of any agreement that could be interpreted as such; (c) your employment with Interleukin does not violate any order,
judgment or injunction applicable to you, and you have provided Interleukin with a copy of any such order, judgment, or injunction;
and (d) all facts you have presented to Interleukin are accurate and true, including all oral and written statements you
have made to Interleukin pertaining to your education, training, qualifications, licensing and prior work experience on any job
application, resume or c.v., or in any interview or discussion with Interleukin.

 

7.Confidentiality
and Intellectual Property. Interleukin considers the protection of its confidential information, proprietary materials
and intellectual property to be extremely important. Consequently, as a condition of this offer of employment, you are required
to sign the enclosed Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement. Prior to accepting
employment with any subsequent employer, you will inform such employer of any restrictions set forth therein which apply to your
activities for or employment by such employer, and permit Interleukin to do the same.

 

    	 	4	 

     

    

 

 

8.General.

 

(a)Entire
Agreement. This Letter Agreement, along with any other agreement specifically referenced herein, constitutes the entire agreement
regarding the terms and conditions of your employment by Interleukin, and supersedes any prior agreements (including the Prior
Agreement), promises or statements (whether oral or written) regarding the offered terms of employment.

 

(b)Modification;
Waiver; Assignment.  This Letter Agreement’s terms may be modified or amended only by written agreement executed by
the parties hereto. This Letter Agreement’s terms may be waived, or consent for the departure therefrom granted, only by
a written document executed by the party entitled to the benefits of such terms or provisions. You may not assign your rights
and obligations hereunder without the prior written consent of Interleukin. Interleukin may assign its rights and obligations
hereunder to any person or entity that succeeds to all or substantially all of Interleukin’s business.

 

(c)Choice
of Law; Venue; Jury Waiver.  This Letter Agreement will be deemed to have been made in Massachusetts, will take effect
as an instrument under seal within Massachusetts, and will be governed by and construed in accordance with the internal law of
Massachusetts, without giving effect to conflict of law principles, and specifically excluding any conflict or choice of law rule
or principle that might otherwise refer construction or interpretation to the law of another jurisdiction. Both you and Interleukin
agree that any action, demand, claim or counterclaim relating to or arising under this Letter Agreement will be commenced in Massachusetts
in a court of competent jurisdiction by a judge alone, and you hereby waive and renounce your right to a trial before a civil
jury.

 

(d)Code Sections
409A and 280G. 

 

(i)The
benefits set forth in Section 5(a) constitute “non-qualified deferred compensation” subject to Section 409A of the
Code. Any termination of your employment triggering payment of benefits under Section 5(a) must constitute a “separation
from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits
can commence. To the extent that the termination of your employment does not constitute a separation of service under Section
409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated
to be provided by you to Interleukin at the time your employment terminates), any benefits payable under Section 5(a) that constitute
deferred compensation under Section 409A will be delayed until after the date of a subsequent event constituting a separation
of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section
will not cause any forfeiture of benefits on your part, but will only act as a delay until such time as a “separation from
service” occurs. Further, if you are a “specified employee” (as that term is used in Section 409A and regulations
and other guidance issued thereunder) on the date your separation from service becomes effective, any benefits payable under Section
5(a) that constitute non-qualified deferred compensation subject to Section 409A will be delayed until the earlier of (A) the
business day following the six-month anniversary of the date your separation from service becomes effective, and (B) the date
of your death, but only to the extent necessary to avoid the adverse tax consequences and penalties under Section 409A; on the
earlier of (X) the business day following the six-month anniversary of the date your separation from service becomes effective,
and (Y) your death, Interleukin will pay you in a lump sum the aggregate value of the non-qualified deferred compensation that
Interleukin otherwise would have paid you prior to that date under Section 5(a). It is intended that each installment of the payments
and benefits provided under Section 5(a) will be treated as a separate “payment” for purposes of Section 409A. Neither
Interleukin nor you will have the right to accelerate or defer the delivery of any such payments or benefits except to the extent
specifically permitted or required by Section 409A.

 

    	 	5	 

     

    

 

 

(ii)The
parties intend this Letter Agreement to be in compliance with Section 409A. You acknowledge and agree that Interleukin does not
guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Letter Agreement, including
but not limited to consequences related to Section 409A. Notwithstanding any other provision to the contrary, this Letter Agreement
will be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section
409A, or the payment of increased taxes, excise taxes or other penalties under Section 409A.

 

(iii)
If any payment or benefit you would receive under this Letter Agreement, when combined with any other payment or benefit you receive
pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (A) constitute a “parachute
payment” within the meaning of Section 280G the Code; and (B) but for this sentence, be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then such Payment will be either: (X) the full amount of such Payment;
or (Y) such lesser amount (with cash payments being reduced before stock option compensation) as would result in no portion of
the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state
and local employments taxes, income taxes, and the Excise Tax, results in your receipt, on an after-tax basis, of the greater
amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

 

[Signature
Page to Follow]

 

    	 	6	 

     

    

 

 

This Letter Agreement
may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument. You may accept this offer of employment and the terms and conditions hereof by signing the enclosed
additional copy of this Letter Agreement.

 

	 	Sincerely,
	 	 	 
	 	INTERLEUKIN GENETICS, INC.
	 	 	 
	 	By:  	/s/ Mark B. Carbeau
	 	 	Mark B. Carbeau
	 	 	Chief Executive Officer

 

Agreed to and Acknowledged:

 

/s/ Kenneth S. Kornman

Signature

 

12/14/2015

Date

 

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]